|
|
Post-transplant consolidation and maintenance, standard risk?Post-transplant consolidation and maintenance, standard risk?In general, what is your preferred consolidation and/or maintenance regimen, if any, for an otherwise healthy 62-year-old patient with standard-risk MM who responds to induction therapy, undergoes autologous stem cell transplant (ASCT) and achieves a CR? Same patient with VGPR or PR post-ASCT?
Attal M et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782-91. Abstract Benboubker L et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371(10):906-17. Abstract McCarthy P et al. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Expert Rev Hematol 2014;7(1):55-66. Abstract McCarthy P et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1770-81. Abstract Palumbo A et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371(10):895-905. Abstract |